February 17, 2025, Intelligence: Late-Breaking Lab News

By Robert Michel | From the Volume XXXII, No. 3 – February 17, 2025 Issue

To implement a corporate restructuring, Becton Dickinson (BD) announced on Feb. 5, 2025, that it would proceed to “separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD.” The company plans to complete this action by the end of 2025. Clinical laboratori…

Read More

---

August 12, 2024, Intelligence: Late-Breaking Lab News

By Robert Michel | From the Volume XXXI, No. 11 – August 12, 2024 Issue

In recent years, many of the national retail pharmacy chain operators announced big plans to open primary care clinics. Now, after substantial investments of billions of dollars, those same retail pharmacy chains are unwinding these business lines. This spring, Walmart announced it w…

Read More

---

November 13, 2023, Intelligence: Late-Breaking Lab News

By Robert Michel | From the Volume XXX, Number 16 – November 13, 2023 Issue

Federal regulators recently confirmed that Dec. 4 remains the deadline for public comment on the proposed rule that the federal Food and Drug Administration (FDA) would use to regulate laboratory developed tests (LDTs). This was confirmed during a public webinar for the lab and in vi…

Read More

---

October 23, 2023, Intelligence: Late-Breaking Lab News

By Robert Michel | From the Volume XXX, Number 15 – October 23, 2023 Issue

Earlier this summer, a 16-year-old completed his bachelor of science degree, along with his certification as a Medical Laboratory Scientist (MLS). The faculty at LSU Health-Shreveport reported that Isak Schmidley, MLS (ASCP)BC is the youngest graduate of its Medical Laboratory Scienc…

Read More

---

November 21, 2022, Intelligence: Late-Breaking Lab News

By Robert Michel | From the Volume XXIX, No. 16 – November 21, 2022 Issue

In yet another employment ripple from the pandemic, a group of more than 75 pathologists penned a letter to Congress urging lawmakers to retain the option for remote diagnostic work. In the letter, which appeared in the Oct. 20 issue of Nature, the pathologists wrote, “During the COVID-19 pa…

Read More

---

Ravgen Gets $272.5 Million Verdict against Labcorp

By Scott Wallask | From the Volume XXIX, No. 15 – October 31, 2022 Issue

CEO SUMMARY: In September, a jury returned a $272.5 million verdict against Labcorp, representing royalties owed to biotech company Ravgen for infringement of its diagnostic genetic test patent. Soon after, Quest Diagnostics settled a similar lawsuit with Ravgen before its tri…

Read More

---

January 31, 2022 Intelligence: Late-Breaking Lab News

By Robert Michel | From the Volume XXIX, No. 2 – January 31, 2022 Issue

DNA-based breast cancer testing is taking a step forward. Illumina in San Diego, which sells next-generation sequencing (NGS) technology, announced a partnership with Agendia in Irvine, Calif., to develop in vitro diagnostic tests for oncology. Agendia offers proprietary breast …

Read More

---

India’s Neuberg Diagnostics Expands into U.S. Market

By Robert Michel | From the Volume XXVIII, No. 11 – August 16, 2021 Issue

“Our idea is to enhance the access and affordability for next-generation techniques, meaning molecular diagnostics, genomics, pathology, digital pathology, proteomics, metabolomics, and all that. This is the spirit behind Neuberg Diagnostics. —GSK Velu, PhD, BPharm …

Read More

---

August 16, 2021 Intelligence: Late-Breaking Lab News

By Robert Michel | From the Volume XXVIII, No. 11 – August 16, 2021 Issue

Elizabeth Holmes, the disgraced ex-CEO of the now-defunct Theranos, continues to be in the news. In the past several weeks, news reports indicate that she gave birth to a child, but whether it is a boy or a girl has not been reported. Also in recent weeks, attorneys have been in court arguing …

Read More

---

Genetic Tests Grow in Number, Complexity

By Robert Michel | From the Volume XXVIII, No. 10 – July 26, 2021 Issue

CEO SUMMARY: Getting paid for genetic tests continues to be a challenge. This is true for both payers and the labs that perform the tests. Even physicians are dissatisfied with the status quo because they must deal with patients unhappy about the high cost of genetic tests. The prob…

Read More

---